Overview
Publication
J Int AIDS Soc. 2019 Aug; 22(8):e25373.
PubMed ID: 31402591
Title
Competing biomedical HIV prevention strategies: Potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA
Authors
Adamson B, Garrison L, Barnabas RV, Carlson JJ, Kublin J, Dimitrov D
Abstract
Promising HIV vaccine candidates are steadily progressing through the clinical trial pipeline. Once available, HIV vaccines will be an important complement but also potential competitor to other biomedical prevention tools such as pre-exposure prophylaxis (PrEP). Accordingly, the value of HIV vaccines and the policies for rollout may depend on that interplay and tradeoffs with utilization of existing products. In this economic modelling analysis, we estimate the cost-effectiveness of HIV vaccines considering their potential interaction with PrEP and condom use.
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.
Related Studies
No related studies